A5036764789- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Surgical Treatments
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Acute Myeloid Leukemia Research
- Radiomics and Machine Learning in Medical Imaging
- Lymphoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Neutropenia and Cancer Infections
- Gastrointestinal Tumor Research and Treatment
- Metastasis and carcinoma case studies
- Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Renal cell carcinoma treatment
- Cancer, Hypoxia, and Metabolism
Paracelsus Medical University
2016-2025
Austrian Breast & Colorectal Cancer Study Group
2024
Lenzing (Austria)
2022-2024
Ludwig Boltzmann Institute for Digital Health and Prevention
2021-2024
Ludwig Boltzmann Institute for Lung Vascular Research
2023-2024
University of Salzburg
2016-2024
Salzburger Landeskliniken
2024
Otto Wagner Hospital
2017-2021
Cancer Research Institute of the Slovak Academy of Sciences
2019-2021
Ludwig Boltzmann Institute for COPD And Respiratory Epidemiology
2017-2019
Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)–programmed (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.
Abstract The development of deep learning (DL) models to predict the consensus molecular subtypes (CMS) from histopathology images (imCMS) is a promising and cost-effective strategy support patient stratification. Here, we investigate whether imCMS calls generated whole slide (WSIs) rectal cancer (RC) pre-treatment biopsies are associated with pathological complete response (pCR) neoadjuvant long course chemoradiotherapy (LCRT) single agent fluoropyrimidine. DL were trained classify WSIs...
Despite durable responses from immune-checkpoint blockade (ICB) in a subset of patients with advanced non-small cell lung cancer (NSCLC), the majority do not derive benefit this treatment. In analysis we evaluated impact concomitant administration antibiotics during initiation ICB on clinical outcome.Advanced non-squamous NSCLC receiving as second- or later line between 2015 and 2017 at our tertiary center Salzburg (Austria) were included. Concomitant use was defined within time frame one...
Immune-checkpoint blockade in front-line or second-line treatment improves survival advanced non-small cell lung cancer (aNSCLC) when compared with chemotherapy alone. However, easily applicable predictive parameters are necessary to guide immune-checkpoint inhibition clinical practice. In this retrospective bi-centric analysis, we investigated the impact of baseline patient and tumor characteristics on outcome aNSCLC patients treated programmed death protein 1(PD-1)/programmed ligand 1...
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity early clinical trials; however, their efficacy the real-world setting is unknown. Methods: A retrospective and safety analysis was performed on data from RET fusion-positive NSCLC patients who participated a access program (named patient protocol) between August 2019 January 2021....
Background: Several serum parameters have been evaluated for adding prognostic value to clinical scoring systems in diffuse large B-cell lymphoma (DLBCL), but none of the reports used multivariate testing more than one parameter at a time. The goal this study was validate widely available their independent impact era National Comprehensive Cancer Network–International Prognostic Index (NCCN-IPI) score determine which were most useful. Patients and Methods: This retrospective bicenter...
Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure hypomethylating agents (HMA). The BCL‐2 inhibitor venetoclax demonstrated activity as monotherapy in combination with chemotherapy or HMA AML. In this case series, patients secondary AML (sAML) not eligible for intensive refractory to were treated within named patient program at our tertiary cancer center Salzburg, Austria. Between April 2017 September 2018, seven sAML received...
Current guidelines of the National Comprehensive Cancer Network and European Society Medical Oncology recommend regorafenib or trifluridine/tipiracil (TAS-102) for third-line therapy metastatic colorectal cancer (mCRC). We evaluated impact TAS-102 treatment on skeletal muscle dynamics sarcopenia.This retrospective analysis was based unselected, consecutive mCRC patients treated with and/or during third later line at our tertiary-care center in Salzburg, Austria. The index (SMI, cm2/m2)...
: Background: Despite modern chemotherapy regimens, survival of patients with locally advanced/metastatic pancreatic cancer remains dismal. Long-term survivors are rare and there no prognostic scores to identify benefitting most from chemotherapy.This retrospective study includes 240 who were treated in a primary palliative setting between the years 2007 2016 single academic institution. Survival rates analyzed using Kaplan-Meier method. Prognostic models including laboratory clinical...
The tumor-microenvironment (TME) represents an attractive therapeutic target in NSCLC and plays important role for efficacy of cancer therapeutics. We hypothesized that upregulation collagen synthesis might be associated with adverse outcome NSCLC. Literature evidence suggests renin-angiotensin system inhibitors (RASi) decrease deposition. Therefore, we aimed to explore the prognostic RASi intake their influence on TME NSCLC.Four publicly available datasets were used evaluate impact key...
Trastuzumab in combination with a platinum and fluorouracil is the treatment of choice for patients advanced human epidermal growth factor receptor 2 (HER2) positive gastric cancer gastroesophageal junction (GEJ) cancer. Pathological assessment HER2 status gastric/GEJ cancer, however, still remains difficult. However, it crucial prerequisite optimal treatment. The GASTRIC-5 registry was designed as an observational, multi-center research initiative comparing local central testing. assessed...
In metastatic colorectal cancer (mCRC), the localization of primary tumour has been shown to be prognostic as well predictive relevance. With aim investigate clinical and molecular disease characteristics with respect sidedness in a real-world cohort, we analyzed 161 mCRC patients included KRAS Registry Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) between January 2006 October 2013. Right-sided displayed worse median overall survival (OS) comparison left-sided (18.1 months [95%-CI:...
Evidence on PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) therapy for advanced non-small-cell lung cancer (NSCLC) is mainly based clinical trials in first- or second-line settings.We aimed to investigate response and prognostic factors with special regard third- later-line therapy.We retrospectively analyzed all patients who had received ICI monotherapy nivolumab, pembrolizumab, atezolizumab NSCLC. Computed tomography evaluations were using evaluation criteria solid tumors (RECIST,...
Men with non-small cell lung cancer (NSCLC) have a more favorable response to immune-checkpoint inhibitor (ICI) monotherapy, while women especially benefit from ICI-chemotherapy (CHT) combinations. To elucidate such sex differences in clinical practice, we retrospectively analyzed two cohorts treated either ICI monotherapy (n = 228) or ICI-CHT combination treatment 80) for advanced NSCLC. Kaplan-Meier analyses were used calculate progression-free (PFS) and overall survival (OS), influencing...